Alexandre de Germay - 03 Mar 2026 Form 4 Insider Report for PFIZER INC (PFE)

Reporting relationship: Executive Vice President
Issuer ticker: PFE
Reported as of: 03 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Mar 2026, 17:24:42 UTC
Prior SEC filing: 06 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Shanice A. Reid, by power of atty, for Alexandre de Germay

Key filing fact

Alexandre de Germay filed Form 4 for PFIZER INC (PFE) on 05 Mar 2026.

Key facts

This page summarizes Alexandre de Germay's Form 4 filing for PFIZER INC (PFE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Mar 2026, 17:24.

Change

Previous filing in this sequence was filed on 06 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002005574 Primary reporting owner

de Germay Alexandre

Relationship: Executive Vice President
Address: 66 HUDSON BOULEVARD EAST, ATTN: CORPORATE SECRETARY, NEW YORK
Signature: /s/ Shanice A. Reid, by power of atty, for Alexandre de Germay
Signature date: 05 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PFE transaction Derivative

Stock Appreciation Rights

Award

Transaction value
Shares: +194,883
Change %
Price: $0.000000^*
Shares after: 194,883
Date: 03 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 194,883
Exercise price: $26.58
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.